Advances in Skin Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 660

Special Issue Editors


E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Corewell Health William Beaumont University Hospital, Royal Oak, MI 48076, USA
Interests: diseases; dermatology; diagnostic innovations; targeted therapies; molecular mechanisms; immunodermatology; translational research; inflammatory skin disorders; clinical dermatology; precision medicine

E-Mail Website
Guest Editor
Department of Plastic and Reconstructive Surgery, Keio University Hospital, Tokyo 160-8582, Japan
Interests: fibroblasts; inflammation; fibrosis; cutaneous wound healing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, entitled “Advances in Skin Diseases”, brings together contemporary research highlighting key developments in the understanding, diagnosis, and treatment of dermatologic conditions. It features contributions that explore novel diagnostic methodologies, emerging therapeutic interventions, and mechanistic insights rooted in molecular biology and immunology. This Special Issue underscores the importance of multidisciplinary collaboration, integrating clinical observations with experimental science to address the complexities of skin disease pathophysiology. By presenting work from leading experts, this collection offers a comprehensive overview of current trends and sets the stage for future innovation in dermatology.

Dr. Nazia M. Saiyed
Dr. Noriko Aramaki-Hattori
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin diseases
  • dermatology
  • diagnostic innovations
  • targeted therapies
  • molecular mechanisms
  • immunodermatology
  • translational research
  • inflammatory skin disorders
  • clinical dermatology
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 5733 KB  
Article
WTAP Suppresses Cutaneous Melanoma Progression by Upregulation of KLF9: Insights into m6A-Mediated Epitranscriptomic Regulation
by Huayu Huang, Dong Li, Yichuan Li, Ying Wang and Jin Yin
Biomedicines 2025, 13(11), 2685; https://doi.org/10.3390/biomedicines13112685 - 31 Oct 2025
Viewed by 434
Abstract
Background: N6-methyladenosine (m6A) modification plays a crucial role in tumor biology; however, the function of the methyltransferase adaptor WTAP in melanoma remains poorly understood. Methods: We analyzed WTAP expression and its clinical relevance using TCGA-SKCM and GTEx datasets, followed by immunohistochemical [...] Read more.
Background: N6-methyladenosine (m6A) modification plays a crucial role in tumor biology; however, the function of the methyltransferase adaptor WTAP in melanoma remains poorly understood. Methods: We analyzed WTAP expression and its clinical relevance using TCGA-SKCM and GTEx datasets, followed by immunohistochemical validation in melanoma tissues. The biological effects of WTAP were assessed through gain- and loss-of-function experiments in melanoma cell lines. Weighted gene co-expression network analysis (WGCNA) and LASSO regression were used to identify key WTAP-related genes. Results: WTAP expression was significantly decreased in melanoma compared with normal skin and was negatively correlated with tumor progression and poor survival. Functionally, WTAP overexpression suppressed melanoma cell proliferation and migration, whereas its knockdown produced the opposite effects. Bioinformatic analyses and rescue experiments identified KLF9 as a potential downstream effector of WTAP. WTAP depletion reduced KLF9 mRNA and protein levels, while overexpression restored them. Moreover, MeRIP-qPCR confirmed that WTAP promotes m6A enrichment on KLF9 mRNA, suggesting a post-transcriptional regulatory mechanism. Conclusions: Our findings reveal a novel WTAP–KLF9 axis that mediates melanoma suppression through m6A-dependent regulation. This study provides new insight into the context-specific role of WTAP in melanoma and suggests it may serve as a potential biomarker or therapeutic target. Full article
(This article belongs to the Special Issue Advances in Skin Diseases)
Show Figures

Figure 1

Back to TopTop